Engineered immune cells target deadly brain cancer in new trial
NCT ID NCT05353530
Summary
This early-stage study is testing the safety and feasibility of a new cell therapy for aggressive brain tumors in adults and children. Doctors will collect a patient's own immune cells, modify them in a lab to better target cancer cells, and then infuse them back into the patient after standard chemotherapy and radiation. The main goal is to see if this personalized treatment is safe and can be reliably manufactured for patients whose tumors have a specific marker called CD70.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Florida Health
Gainesville, Florida, 32608, United States
Conditions
Explore the condition pages connected to this study.